Enrolling By Invitation PHASE1 INTERVENTIONAL 1-arm NCT06896110

Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

Phase 1 Trial of Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma

Sponsor: Andrew P. Groves

Conditions Astrocytoma, IDH-Mutant, Grade 4 Diffuse Hemispheric Glioma, H3 G34-Mutant Diffuse Midline Glioma (DMG) Glioblastoma (GBM) Gliosarcoma of Brain

Interventions Azacitidine (AZA) MRI Contrast Nivolumab lumbar puncture

Updated 3 times since 2025 Last updated: Jun 20, 2025 Started: Jun 5, 2025 Primary completion: Mar 31, 2027 Completion: Mar 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Astrocytoma, IDH-Mutant, Grade 4 and Diffuse Hemispheric Glioma, H3 G34-Mutant, this trial is ongoing. The trial is conducted by Andrew P. Groves and has accumulated 3 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Jul 2025 — Present [monthly]

Enrolling By Invitation PHASE1

Status: Not Yet Recruiting → Enrolling By Invitation
Jun 2025 — Jul 2025 [monthly]

Not Yet Recruiting PHASE1
Apr 2025 — Jun 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Andrew P. Groves

Data source: University of Iowa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Iowa City, United States